Navigation Links
Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
Date:3/18/2009

SAN FRANCISCO, March 18 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it has received written permission from the U.S. Food and Drug Administration (FDA) to begin a pivotal Phase 3 trial of MDV3100, its novel androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed docetaxel-based chemotherapy. The placebo-controlled, double-blind, multinational trial will enroll approximately 1,200 patients who will be randomized (2:1) to receive either MDV3100 or placebo. The primary endpoint of the trial will be overall survival.

"This is a significant milestone in the development of this important novel investigational drug," said David T. Hung, M.D., president and chief executive officer of Medivation. "We look forward to starting the trial and rapidly executing a comprehensive Phase 3 development program for MDV3100. Given the encouraging results seen to date in our ongoing Phase 1-2 trial and the limited life expectancy of men with CRPC who have failed chemotherapy, we will work to begin the Phase 3 clinical development of MDV3100 as quickly as possible this year."

The FDA informed the Company that it could test a dose of MDV3100 up to 240mg/day. There are no driving or other restrictions placed on the activities of participants in the trial. Final trial specifics will be announced when the first patient is enrolled.

MDV3100 Ongoing Phase 1-2 Trial

MDV3100 is being evaluated in an ongoing open-label, U.S., Phase 1-2 study of a total of 140 men with CRPC. Patients in this trial were heavily pretreated, with all having failed standard hormonal therapies and many having also failed docetaxel-based chemotherapy. MDV3100 has consistently demonstrated encouraging anti-tumor activity across dose levels and endpoints
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
2. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
3. Medivation Announces Participation in Upcoming Conferences
4. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
5. Medivation Announces Participation in Upcoming Conferences
6. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
7. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
8. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
9. Urban Health Plan Receives $1.3M from Economic Stimulus Package to Increase Health Care Access in Corona, Queens
10. CUREXO Technology Corporation Receives Quality Certificate
11. Silk Information Systemss Silk V 4.2 Receives 08 CCHIT Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Workflow in labs has greatly ... in the last decade. New features such as multiplexing, microfluidics, and integration ... where do lab managers, technicians, and researchers find handy metrics to compare and ...
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... According ... and the American Heart Association have released new guidelines to educate doctors and patients ... last update to these particular guidelines came in 2007, so the new version is ...
(Date:8/27/2015)... ... 2015 , ... Thriveology Founders, Dr. Carly Letzt Carney and Dr. Mark Carney ... in Denver, Colorado on Saturday, August 29, 2015 at the Marriott DTC, 4900 S. ... health authorities, and will present a two part seminar entitled, “How to Thrive as ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... exploding legal marijuana industry with the launch of its Doobster platform, a HIPAA-compliant ... to order products from their smart phones and tablets. Well, Doobster, “The ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... Hurricane Katrina slammed into the Gulf Coast, killing more than 1,800 people, displacing ... according to a Georgia State University study. , While most people don’t develop ...
Breaking Medicine News(10 mins):Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 2Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 3Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2
... change habits, but social shame works even better, suggests a ... disease rates blamed on the microbial pathogens that cause diarrhea ... workers there just beating their heads against the reality of ... to change it," said Subhrendu Pattanayak, an associate professor at ...
... Unlike other forms of suicide, physician assisted death does ... among surviving family members. In addition, the prevalence and ... loved ones received aid in dying is no different ... physician assisted suicide. These findings are the result of ...
... ... Administration (USFDA) will host Assessing Benefits and Risks of Medicinal Products in Regulatory Decisions from ... ... (DIA) and the US Food and Drug Administration (USFDA) will host Assessing Benefits ...
... researchers , WEDNESDAY, Sept. 30 (HealthDay News) -- Non-AIDS-related ... more common among HIV patients than among people without ... to treat people with the virus, U.S. researchers say. ... are at increased risk for so-called AIDS-defining malignancies, which ...
... to 49 are 19 times more likely to have memory ... Former professional football players suffer from Alzheimer,s disease or other ... a new study commissioned by the National Football League shows. ... 49 are 19 times more likely to struggle with memory ...
... ... selected Water For People to provide technical support for a 31-million-euro initiative funded by ... drinking water and improved sanitation to more than 540,000 people in 21 low-income areas ... ...
Cached Medicine News:Health News:Peer pressure builds more latrines than financial assistance 2Health News:Peer pressure builds more latrines than financial assistance 3Health News:Physician-assisted suicide does not increase severity of depression, grief among family members 2Health News:Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop 2Health News:Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop 3Health News:Non-AIDS-Related Cancers Growing Among HIV Patients 2Health News:Dementia Risk Higher for NFL Players 2Health News:Dementia Risk Higher for NFL Players 3Health News:Dementia Risk Higher for NFL Players 4Health News:Dementia Risk Higher for NFL Players 5Health News:Dementia Risk Higher for NFL Players 6Health News:Water For People Selected for $1.56 Million Project in Africa 2Health News:Water For People Selected for $1.56 Million Project in Africa 3Health News:Water For People Selected for $1.56 Million Project in Africa 4
(Date:8/27/2015)... 2015 According to a new ... (Integrated, Standalone), by Deployment Mode (Web based, On-Premise, Cloud-Based), ... Service Providers), by Component - Global Trends & Forecast ... estimated at $501.1 Million 2014, and is projected to ... 7.6% from 2014 to 2019. Browse ...
(Date:8/27/2015)... , Aug. 27, 2015  BioElectronics Corporation (OTC Pink: BIEL), ... that three abstracts featuring the use of ActiPatch®, its ... 9 th Congress of the European Pain Federation ... September 2015. The Company will also be exhibiting ... Gianluca Bagnato , department clinical and experimental rheumatology ...
(Date:8/27/2015)... YORK , Aug. 27, 2015   Americord ... cord tissue , and placenta tissue banking ... cord blood banking e-commerce website. This new website makes ... ever with an interactive shopping cart and checkout process. ... "Most cord blood banking websites make this service ...
Breaking Medicine Technology:Radiology Information Systems Market Worth $722.7 Million by 2019 2Radiology Information Systems Market Worth $722.7 Million by 2019 3Radiology Information Systems Market Worth $722.7 Million by 2019 4BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2Cord Blood Bank Revolutionizes Process of Online Cord Blood Banking 2
... PhotoMedex, Inc. (Nasdaq: PHMD ) announced ... current clinical trial being performed by John Y.M. Koo, ... of California, San Francisco. Dr. Koo,s experimental treatment protocol ... from moderate to severe psoriasis. The study, which utilizes ...
... Awarepoint Corporation announced today that CEO Jay Deady will ... Healthcare Innovation Summit on April 14, 10:30 a.m. – ... York. Joining Deady on the panel will be Harry Greenspun, ... Safavi, M.D., vice president and global lead of the Cisco ...
Cached Medicine Technology:Clinical Trial Offers New Hope for Moderate to Severe Psoriasis Sufferers 2Clinical Trial Offers New Hope for Moderate to Severe Psoriasis Sufferers 3Awarepoint CEO Jay Deady to Serve as Panelist at IBF's Digital Healthcare Innovation Summit 2Awarepoint CEO Jay Deady to Serve as Panelist at IBF's Digital Healthcare Innovation Summit 3
QualCraft™ Euro Lite has a molded nylon frame that fits most faces. Universal keyhole nose bridge fits narrow to average noses. Available with or without lead vinyl-lined side shields....
QualCraft™ Radiation-Reducing Eyewear is 50% lighter than other protective eyewear. Manufactured for the ultimate combination of comfort, function, and protection....
Clip-On Glasses clip onto regular eyewear frames. Plano (nonprescription) only. Will not fit over high-plus or high-minus presciptions, or over glasses with thick frames. Black wire frames. Wt. 63 g....
Portable shields for your safety and convenience....
Medicine Products: